Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemo-IO followed by Maintenance Pembro + Sacituzumab in ES-SCLC
NCT06667167Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in small cell lung cancer (SCLC). Primary endpoint: Progression Free Survival at 100 months. Started Dec 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06667167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667167.